By modulating mitochondrial metabolism, it prevents the over-activation of mTOR , a key nutrient sensor that, when overactive, is linked to neurodegeneration and inflammation. 🧠 Therapeutic Applications
-sparing , meaning it avoids many common side effects like weight gain and fluid retention. Core Pharmacology and Mechanism msdc 0160 buy
MSDC-0160 works by selectively binding to and inhibiting the , a protein complex in the inner mitochondrial membrane. By modulating mitochondrial metabolism
In preclinical models, MSDC-0160 protected dopaminergic neurons, improved motor function, and reduced neuroinflammation. it prevents the over-activation of mTOR
MSDC-0160 is a novel, clinical-stage drug candidate originally developed for . It is the prototype of a new class of insulin sensitizers called mTOT Modulators (Mitochondrial Target of Thiazolidinediones). Unlike first-generation insulin sensitizers like pioglitazone, MSDC-0160 is PPAR
By modulating mitochondrial metabolism, it prevents the over-activation of mTOR , a key nutrient sensor that, when overactive, is linked to neurodegeneration and inflammation. 🧠 Therapeutic Applications
-sparing , meaning it avoids many common side effects like weight gain and fluid retention. Core Pharmacology and Mechanism
MSDC-0160 works by selectively binding to and inhibiting the , a protein complex in the inner mitochondrial membrane.
In preclinical models, MSDC-0160 protected dopaminergic neurons, improved motor function, and reduced neuroinflammation.
MSDC-0160 is a novel, clinical-stage drug candidate originally developed for . It is the prototype of a new class of insulin sensitizers called mTOT Modulators (Mitochondrial Target of Thiazolidinediones). Unlike first-generation insulin sensitizers like pioglitazone, MSDC-0160 is PPAR